These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19737968

  • 1. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
    Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP.
    Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
    [Abstract] [Full Text] [Related]

  • 2. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.
    Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP.
    Mol Cancer Ther; 2007 Jan; 6(1):93-100. PubMed ID: 17237269
    [Abstract] [Full Text] [Related]

  • 4. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 5. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.
    Clin Cancer Res; 2011 Jul 01; 17(13):4451-61. PubMed ID: 21571868
    [Abstract] [Full Text] [Related]

  • 6. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES.
    Int J Cancer; 2015 Jul 15; 137(2):267-77. PubMed ID: 25471734
    [Abstract] [Full Text] [Related]

  • 7. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
    Clin Cancer Res; 2009 Jun 15; 15(12):4147-56. PubMed ID: 19509167
    [Abstract] [Full Text] [Related]

  • 8. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
    Cancer Sci; 2007 Sep 15; 98(9):1498-503. PubMed ID: 17627612
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
    Bijman MN, van Berkel MP, Kok M, Janmaat ML, Boven E.
    Anticancer Drugs; 2009 Jul 15; 20(6):450-60. PubMed ID: 19369859
    [Abstract] [Full Text] [Related]

  • 10. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.
    Cancer Res; 2008 Jul 15; 68(14):5878-87. PubMed ID: 18632642
    [Abstract] [Full Text] [Related]

  • 11. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A.
    Int J Oncol; 2012 Sep 15; 41(3):1128-38. PubMed ID: 22684500
    [Abstract] [Full Text] [Related]

  • 12. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C, PENELOPE trial investigators.
    Int J Gynecol Cancer; 2019 Sep 15; 29(7):1141-1147. PubMed ID: 31420414
    [Abstract] [Full Text] [Related]

  • 13. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
    Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.
    PLoS One; 2017 Sep 15; 12(5):e0177331. PubMed ID: 28493933
    [Abstract] [Full Text] [Related]

  • 14. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
    Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.
    Cancer Res; 2013 Aug 15; 73(16):5183-94. PubMed ID: 23780344
    [Abstract] [Full Text] [Related]

  • 15. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.
    Int J Oncol; 2007 Feb 15; 30(2):509-20. PubMed ID: 17203234
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U.
    J Clin Oncol; 2010 Mar 01; 28(7):1215-23. PubMed ID: 19901115
    [Abstract] [Full Text] [Related]

  • 20. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
    Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C.
    Oncotarget; 2014 Aug 30; 5(16):7138-48. PubMed ID: 25216528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.